Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Grete Semb

Showing results (91-100 of 119) with videos related to

Pageof 12
Sort By:
RMD Open|June 24, 2026
Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Miguel A Gonzalez-Gay, Virginia Pascual-Ramos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 7, 2024
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysisPaul M Haller, Niema Kazem, Stefan Agewall, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyMaria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
Plos One|April 25, 2013
Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritisMarthe T Maehlen, Sella A Provan, Diederik P C de Rooy, et al.
RMD Open|July 20, 2020
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbiditiesTore K Kvien, Alejandro Balsa, Neil Betteridge, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Pageof 12

Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
RMD Open|June 24, 2026
Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Miguel A Gonzalez-Gay, Virginia Pascual-Ramos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 29, 2022
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyJuan Tamargo, Keld Per Kjeldsen, Eva Delpón, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 7, 2024
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysisPaul M Haller, Niema Kazem, Stefan Agewall, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyMaria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
Plos One|April 25, 2013
Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritisMarthe T Maehlen, Sella A Provan, Diederik P C de Rooy, et al.
RMD Open|July 20, 2020
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbiditiesTore K Kvien, Alejandro Balsa, Neil Betteridge, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 28, 2021
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapyHeinz Drexel, Stuart J Pocock, Basil S Lewis, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 31, 2021
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyEmma F Magavern, Juan Carlos Kaski, Richard M Turner, et al.
Pageof 12